血栓与止血学
血栓與止血學
혈전여지혈학
CHINESE JOURNAL OF THROMBOSIS AND HEMOSTASIS
2014年
3期
117-120
,共4页
肖辉%陈冠瑶%林康华%宁观林
肖輝%陳冠瑤%林康華%寧觀林
초휘%진관요%림강화%저관림
稳定型心绞痛%别嘌醇
穩定型心絞痛%彆嘌醇
은정형심교통%별표순
Allopurinol%Chronic stable angina
目的:探讨别嘌醇对改善稳定型心绞痛患者缺血症状的有效性及安全性。方法入选就诊于我院的65例稳定型心绞痛患者,所有患者行运动平板试验。通过计算机随机化法将患者随机分为别嘌醇(100 mg/d)治疗组和安慰剂组。主要研究终点是治疗6个月后运动起始至发生ST段压低的时间,次要终点是总运动时间和运动起始到心绞痛发作的时间。结果在第一个治疗周期,分析了28例别嘌醇组(共31例)和32例安慰剂组患者(共34例)。在第二个周期,分析所有入选的60例患者。别嘌醇组发生ST段压低的平均时间从基线的232 s( IQR 182-380)增加到298 s( IQR 211-408),而安慰剂组则增加到249 s(200-375,P=0.0002)。估计值为43 s(两组存在显著差异)(95%CI,31-58)。别嘌醇将平均总运动时间从基线的301 s(IQR 251-447)增加到393 s(IQR 280-519),而安慰剂组则增加到307 s(232-430;P=0.0003);估计值为58 s(95%CI 45-77)。别嘌醇将心痛发作时间从基线的234 s(IQR 189-382)增加到304 s(IQR 222-421),安慰剂组则增加到272 s(200-380;P=0.001);估计值为38 s(95%CI 17-55)。别嘌醇组未见不良反应发生。结论别嘌醇对预防心肌缺血缺氧具有一定的疗效,有助于患者增强身体活动能力和缓解心绞痛症状。
目的:探討彆嘌醇對改善穩定型心絞痛患者缺血癥狀的有效性及安全性。方法入選就診于我院的65例穩定型心絞痛患者,所有患者行運動平闆試驗。通過計算機隨機化法將患者隨機分為彆嘌醇(100 mg/d)治療組和安慰劑組。主要研究終點是治療6箇月後運動起始至髮生ST段壓低的時間,次要終點是總運動時間和運動起始到心絞痛髮作的時間。結果在第一箇治療週期,分析瞭28例彆嘌醇組(共31例)和32例安慰劑組患者(共34例)。在第二箇週期,分析所有入選的60例患者。彆嘌醇組髮生ST段壓低的平均時間從基線的232 s( IQR 182-380)增加到298 s( IQR 211-408),而安慰劑組則增加到249 s(200-375,P=0.0002)。估計值為43 s(兩組存在顯著差異)(95%CI,31-58)。彆嘌醇將平均總運動時間從基線的301 s(IQR 251-447)增加到393 s(IQR 280-519),而安慰劑組則增加到307 s(232-430;P=0.0003);估計值為58 s(95%CI 45-77)。彆嘌醇將心痛髮作時間從基線的234 s(IQR 189-382)增加到304 s(IQR 222-421),安慰劑組則增加到272 s(200-380;P=0.001);估計值為38 s(95%CI 17-55)。彆嘌醇組未見不良反應髮生。結論彆嘌醇對預防心肌缺血缺氧具有一定的療效,有助于患者增彊身體活動能力和緩解心絞痛癥狀。
목적:탐토별표순대개선은정형심교통환자결혈증상적유효성급안전성。방법입선취진우아원적65례은정형심교통환자,소유환자행운동평판시험。통과계산궤수궤화법장환자수궤분위별표순(100 mg/d)치료조화안위제조。주요연구종점시치료6개월후운동기시지발생ST단압저적시간,차요종점시총운동시간화운동기시도심교통발작적시간。결과재제일개치료주기,분석료28례별표순조(공31례)화32례안위제조환자(공34례)。재제이개주기,분석소유입선적60례환자。별표순조발생ST단압저적평균시간종기선적232 s( IQR 182-380)증가도298 s( IQR 211-408),이안위제조칙증가도249 s(200-375,P=0.0002)。고계치위43 s(량조존재현저차이)(95%CI,31-58)。별표순장평균총운동시간종기선적301 s(IQR 251-447)증가도393 s(IQR 280-519),이안위제조칙증가도307 s(232-430;P=0.0003);고계치위58 s(95%CI 45-77)。별표순장심통발작시간종기선적234 s(IQR 189-382)증가도304 s(IQR 222-421),안위제조칙증가도272 s(200-380;P=0.001);고계치위38 s(95%CI 17-55)。별표순조미견불량반응발생。결론별표순대예방심기결혈결양구유일정적료효,유조우환자증강신체활동능력화완해심교통증상。
Objective We ascertained whether allopurinol prolongs exercise capability in patients with chronic stable angina .Methods 65 patients with angiographically documented coronary artery disease , a positive exercise tolerance test ,and stable chronic angina pectoris ( for at least 2 months ) were recruited into a double-blind,randomised,placebo-controlled,crossover study in the hospital .We used computer-generated randomisation to assign patients to allopurinol (100 mg per day) or placebo for 6 weeks before crossover .Our primary endpoint was the time to ST depression ,and the secondary endpoints were total exercise time and time to chest pain .Results In the first treatment period ,31 patients were allocated to allopurinol and 28 were an-alysed ,and 34 were allocated to placebo and 32 were analysed .In the second period ,all 60 patients were ana-lysed.Allopurinol increased the median time to ST depression to 298 s(IQR 211-408)from a baseline of 232 s(182-380),and placebo increased it to 249 s(200-375;P=0.0002).The point estimate(absolute differ-ence between allopurinol and placebo )was 43 s(95%CI 31-58).Allopurinol increased median total exercise time to 393 s(IQR 280-519)from a baseline of 301 s(251-447),and placebo increased it to 307 s(232-430;P=0.0003);the point estimate was 58 s(95%CI 45-77) .Allopurinol increased the time to chest pain from a baseline of 234 s ( IQR 189-382 ) to 304 s ( 222-421 ) , and placebo increased it to 272 s ( 200-380;P=0.001);the point estimate was 38 s(95%CI 17-55).No adverse effects of treatment were reported .Conclu-sion Allopurinol is a useful anti-ischaemic treatment option in patients with angina that has the advantage of being inexpensive ,well tolerated and safe in the long term .